Navigation Links
NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines

ROCKVILLE, Md., July 27 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the issuance of U.S. Patent No. 7,763,450 for "Functional Influenza Virus-Like Particles (VLPS)".  The patent covers the use of influenza gene sequences for high-yield production of consistent influenza VLP vaccines to protect against current and future seasonal and pandemic strains of influenza viruses.

Novavax's newly patented influenza vaccine technology utilizes hemagglutinin (HA) and neuraminidase (NA), major proteins found on the surface of the influenza virus together with a single influenza matrix 1 (M1) protein, to form the core of the influenza VLP.  As new influenza strains emerge, Novavax's technology allows HA and NA to be engineered to match strains recommended by U.S. and world health regulatory authorities and then combined with a universal M1 protein.  Novavax has identified an M1 protein that efficiently forms VLPs from multiple influenza strains, including the human A and B strains that are currently responsible for the disease world wide.  This process promotes rapid and efficient production of VLPs that have a more uniform shape and size, which Novavax believes will add to the consistency and safety of its vaccines.

"Our VLP technology overcomes a major limitation of the current influenza virus vaccine technology that depends on strain selection and optimization every year.  It enables faster production of vaccine for the target influenza strain than the existing, egg-based process which resulted in significant delays in the manufacture of vaccines during the 2009 H1N1 pandemic emergency," said Dr. Gale Smith, Vice President of Vaccine Development at Novavax and one of the senior inventors of the VLP technology.

"This patent strengthens our competitive position around our core technology that allows us to produce recombinant influenza VLP vaccines.  We are grateful to our scientific team that pioneered this innovative and elegant approach to manufacturing efficient, high-quality, immunogenic influenza vaccines," said Dr. Rahul Singhvi, President and CEO of Novavax.

About Novavax

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website:

Forward Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the ability of Novavax to effectively maintain and defend its technology patents and patent applications in the United States and in the rest of the world; the early stage of Novavax's product candidates under development; current results may not be predictive of future results; further testing is required before an IND may be filed with the FDA and human clinical trials can begin; uncertainties relating to clinical trials; results in human clinical trials may not be consistent with animal study results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further preclinical work and clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at These forward looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010
2. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
3. NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results
4. NOVAVAX to Present at 22nd Annual ROTH OC Growth Stock Conference
5. NOVAVAX to Present at Cowen and Companys 30th Annual Health Care Conference
6. NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
7. Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
8. NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock
9. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
10. Novavax to Present at 8th Annual BIO Investor Forum 2009
11. Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):